Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial-Reference-Cited by-同舟云学术

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

Published:2023-10 Issue:10 Volume:10 Page:e813-e824
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Dimopoulos Meletios A,Terpos Evangelos,Boccadoro Mario,Delimpasi Sosana,Beksac Meral,Katodritou Eirini,Moreau Philippe,Baldini Luca,Symeonidis Argiris,Bila Jelena,Oriol Albert,Mateos Maria-Victoria,Einsele Hermann,Orfanidis Ioannis,Kampfenkel Tobias,Liu Weiping,Wang Jianping,Kosh Michele,Tran NamPhuong,Carson Robin,Sonneveld Pieter

Publisher

Elsevier BV

Subject

Hematology

Reference31 articles.

1. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors;de Weers;J Immunol,2011

2. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79;Lammerts van Bueren;Blood,2014

3. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma;Overdijk;MAbs,2015

4. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking;Overdijk;J Immunol,2016

5. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma;Krejcik;Blood,2016

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Early Relapse: Non-CAR T Cells;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide;Expert Review of Hematology;2024-07-27

3. Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China;Cancer Medicine;2024-05

4. Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data;Blood Neoplasia;2024-03

5. Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma;European Journal of Haematology;2024-02-21